FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1969093886> ?p ?o ?g. }

• W1969093886 endingPage "4059" @default.
• W1969093886 startingPage "4049" @default.
• W1969093886 abstract "Abstract BACKGROUND: Lonafarnib (LNF) is a protein farnesyl transferase (FTase) inhibitor that has shown synergistic activity with taxanes in preclinical models and early stage clinical trials. Preclinical findings suggested tubulin acetylation and FTase expression levels may be important determinants of drug sensitivity that would help identify patient populations more likely to benefit from this regimen. This pilot study evaluated the biological effects of LNF and docetaxel (DTX) combination therapy in refractory solid tumors by comparing pretreatment and post‐treatment tumor biopsies. METHODS: Patients with histologically confirmed locally advanced or metastatic solid malignancies refractory to standard therapies or with no effective therapies available were eligible. Patients were randomized to 1 of 4 dosing cohorts: 1) 30 mg/m 2 , 100 mg; 2) 36 mg/m 2 , 100 mg; 3) 30 mg/m 2 , 150 mg; or 4) 36 mg/m 2 , 150mg of DTX intravenously weekly, LNF orally twice daily, respectively. RESULTS: Of the 38 patients enrolled, 36 were treated, and 29 were evaluable for toxicity and response assessment. The combination of LNF and DTX was tolerated in all cohorts with the exception of a 28% incidence of grade 3/4 diarrhea, which was manageable with aggressive antidiarrheal regimens. Seven patients derived clinically meaningful benefit from this combination treatment; these patients had significantly lower basal FTase‐beta mRNA expression levels than the mean study population level ( P < .05). Correlation of clinical benefit with tubulin acetylation content as well as basal acetyl‐tubulin content were evaluated. However, no significant correlation was found. CONCLUSIONS: Despite the small number of patients, these findings support our preclinical mechanistic studies and warrant further clinical investigations using FTase‐beta mRNA expression as a potential predictive biomarker to select for an enriched patient population to study the effects of taxane and FTase inhibitor combination therapies. Cancer 2011. © 2011 American Cancer Society." @default.
• W1969093886 created "2016-06-24" @default.
• W1969093886 creator A5003397614 @default.
• W1969093886 creator A5010399375 @default.
• W1969093886 creator A5022930216 @default.
• W1969093886 creator A5023832620 @default.
• W1969093886 creator A5036672833 @default.
• W1969093886 creator A5037163615 @default.
• W1969093886 creator A5043235685 @default.
• W1969093886 creator A5053707957 @default.
• W1969093886 creator A5055989413 @default.
• W1969093886 creator A5056305413 @default.
• W1969093886 creator A5059710197 @default.
• W1969093886 creator A5064924657 @default.
• W1969093886 creator A5071996306 @default.
• W1969093886 creator A5087992755 @default.
• W1969093886 creator A5088178599 @default.
• W1969093886 date "2011-03-01" @default.
• W1969093886 modified "2023-10-12" @default.
• W1969093886 title "Farnesyl transferase expression determines clinical response to the docetaxel-lonafarnib combination in patients with advanced malignancies" @default.
• W1969093886 cites W1873121398 @default.
• W1969093886 cites W1955547739 @default.
• W1969093886 cites W1969998496 @default.
• W1969093886 cites W1972540178 @default.
• W1969093886 cites W2008431826 @default.
• W1969093886 cites W2016841603 @default.
• W1969093886 cites W2017098460 @default.
• W1969093886 cites W2031646505 @default.
• W1969093886 cites W2035363409 @default.
• W1969093886 cites W2036699032 @default.
• W1969093886 cites W2043901171 @default.
• W1969093886 cites W2053261571 @default.
• W1969093886 cites W2059431360 @default.
• W1969093886 cites W2060157376 @default.
• W1969093886 cites W2068433296 @default.
• W1969093886 cites W2074322827 @default.
• W1969093886 cites W2075277027 @default.
• W1969093886 cites W2077302626 @default.
• W1969093886 cites W2077861570 @default.
• W1969093886 cites W2086589373 @default.
• W1969093886 cites W2089642031 @default.
• W1969093886 cites W2091728648 @default.
• W1969093886 cites W2118053238 @default.
• W1969093886 cites W2128392882 @default.
• W1969093886 cites W2135372494 @default.
• W1969093886 cites W2136643719 @default.
• W1969093886 cites W2140473755 @default.
• W1969093886 cites W2142919712 @default.
• W1969093886 cites W2145978772 @default.
• W1969093886 cites W2154094988 @default.
• W1969093886 cites W2154468846 @default.
• W1969093886 cites W2158788722 @default.
• W1969093886 cites W2160553642 @default.
• W1969093886 cites W2161177517 @default.
• W1969093886 cites W2164553008 @default.
• W1969093886 cites W2166435019 @default.
• W1969093886 cites W2170468070 @default.
• W1969093886 cites W2337358073 @default.
• W1969093886 doi "https://doi.org/10.1002/cncr.26004" @default.
• W1969093886 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3131496" @default.
• W1969093886 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21365629" @default.
• W1969093886 hasPublicationYear "2011" @default.
• W1969093886 type Work @default.
• W1969093886 sameAs 1969093886 @default.
• W1969093886 citedByCount "16" @default.
• W1969093886 countsByYear W19690938862012 @default.
• W1969093886 countsByYear W19690938862013 @default.
• W1969093886 countsByYear W19690938862015 @default.
• W1969093886 countsByYear W19690938862017 @default.
• W1969093886 countsByYear W19690938862020 @default.
• W1969093886 countsByYear W19690938862021 @default.
• W1969093886 countsByYear W19690938862023 @default.
• W1969093886 crossrefType "journal-article" @default.
• W1969093886 hasAuthorship W1969093886A5003397614 @default.
• W1969093886 hasAuthorship W1969093886A5010399375 @default.
• W1969093886 hasAuthorship W1969093886A5022930216 @default.
• W1969093886 hasAuthorship W1969093886A5023832620 @default.
• W1969093886 hasAuthorship W1969093886A5036672833 @default.
• W1969093886 hasAuthorship W1969093886A5037163615 @default.
• W1969093886 hasAuthorship W1969093886A5043235685 @default.
• W1969093886 hasAuthorship W1969093886A5053707957 @default.
• W1969093886 hasAuthorship W1969093886A5055989413 @default.
• W1969093886 hasAuthorship W1969093886A5056305413 @default.
• W1969093886 hasAuthorship W1969093886A5059710197 @default.
• W1969093886 hasAuthorship W1969093886A5064924657 @default.
• W1969093886 hasAuthorship W1969093886A5071996306 @default.
• W1969093886 hasAuthorship W1969093886A5087992755 @default.
• W1969093886 hasAuthorship W1969093886A5088178599 @default.
• W1969093886 hasBestOaLocation W19690938862 @default.
• W1969093886 hasConcept C121332964 @default.
• W1969093886 hasConcept C126322002 @default.
• W1969093886 hasConcept C142424586 @default.
• W1969093886 hasConcept C143998085 @default.
• W1969093886 hasConcept C2776694085 @default.
• W1969093886 hasConcept C2776999253 @default.
• W1969093886 hasConcept C2778024521 @default.
• W1969093886 hasConcept C2779306644 @default.
• W1969093886 hasConcept C2781190966 @default.

• next